Clinical Trials Logo

Clinical Trial Summary

This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China


Clinical Trial Description

Orelabrutinib is a novel BTK inhibitor with high selectivity and has been approved in China for relapsed/refractory CLL/SLL,, The purpose of this study is to describe the effectiveness and safety of orelabrutinib of chronic lymphocytic leukemia (CLL) in real world. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05975164
Study type Observational
Source Shandong University
Contact Wei Li
Phone 18560089739
Email liwei_medicine@163.com
Status Not yet recruiting
Phase
Start date July 25, 2023
Completion date July 10, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05487651 - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies Phase 1
Recruiting NCT05590702 - French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings
Withdrawn NCT04660045 - Early Intervention With Acalabrutinib in Patients With High Risk CLL Phase 2
Recruiting NCT04215809 - Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL Phase 1
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1
Withdrawn NCT05365100 - A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL Phase 1/Phase 2
Recruiting NCT04775745 - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Phase 1
Not yet recruiting NCT05918276 - Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL Phase 2
Recruiting NCT05920668 - Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
Recruiting NCT05269940 - A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05491044 - A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib Phase 2
Withdrawn NCT05176691 - HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Phase 1
Terminated NCT04149821 - Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy Phase 2
Recruiting NCT04523428 - REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) Phase 2
Withdrawn NCT04694560 - A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Recruiting NCT06104566 - Global Trial in APG2575 for Patients With CLL/SLL Phase 3
Recruiting NCT06319456 - A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Phase 3
Active, not recruiting NCT03493217 - A Study to Evaluate ICP-022 in Patients With CLL/ SLL Phase 1/Phase 2
Recruiting NCT05791409 - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL Phase 1/Phase 2